Antipsychotics to Drive the US Generics Market
With the major drugs going off-patent and government promotion on rise, the US generics market has crossed the mark of US$ 80 Billion in 2010.

The report finds out that, substantial growth in antipsychotics generic drugs are likely to be the next key development in the US generics market. Patent expiration of Seroquel and Zyprexa will propel the level of competition among generic players and the market will receive a strong growth momentum. Moreover, players' focus to manufacture low cost drugs will act as a major growth contributor.
The report "Booming US Generic Drug Market" presents the overall US generics market in an effective manner and broadly evaluates the current trends and their impact on the industry revenue. Under the regulatory environment, several key initiatives of the US government towards generics is outlined and discussed. These acts are important for clients to know as they depict the role of respective authorities in making viable laws.
The report is an outcome of an extensive research and prudent analysis of the US generics market that provides reliable statistics and proper content flow. Forecasting in the report makes use of effective methods and techniques so that outlook may be realistic in nature. The description and key activities of active market players further enrich clients with information related to private sector participation.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM589.htm
Check DISCOUNTED REPORTS on: http://www.rncos.com/promotion.htm
About RNCOS:
RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals study and analyze the industry and its various components, with comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the consultants in meeting their objectives in a cost-effective and timely manner.
###
Tag Words:
generics market us
Categories: Health
Press Release Contact
B-129, Sector 6 Noida - 201301
91-120-4224-700
91-120-4224-707
B-129, Sector 6 Noida - 201301
91-120-4224-700
91-120-4224-707